AHA 2021: SGLT2 is Associated with Reduction in Atrial-Arrythmic Events | Dr Ilan Goldenberg

Подробнее о видео

Watch on Radcliffe Cardiology:

In this interview, Dr Illan Goldenberg (University of Rochester Medical Center, Rochester, NY, US) presents the findings of a study aiming to evaluate the effect of SGLT2is on atrial arrhythmia burden in patients with ICDs. Originally revealed at AHA 2021, the results suggest that treatment with SGLT2 inhibitors was associated with a significant reduction in the risk of total atrial arrhythmic events and all-cause mortality.

Discussion points:
-Background Study
-Design and Patient Population
-Key Findings
-Take-Home Messages
-Next Steps

Recorded remotely from New York, 2021.

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.